// App-Quantinova.ai

1641 : Final Results of the BP22333 Study Demonstrate Non-Inferior Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Administration of Rituximab Compared with Intravenous (IV) Administration As Maintenance Therapy in Patients with Follicular Lymphoma (FL)

Researchers

Presenter

  • Irit Avivi

Principal Investigators

  • Jean-Francois Larouche

  • Andrea Janikova

  • Juliana Pereira

  • Mike Brewster

  • Olivier Catalani

  • Christine McIntyre

  • Pakeeza Sayyed

  • Andrew Haynes

Medical Centers

  • Rambam Medical Center, Haifa, Israel

  • Dept. of Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic

  • Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom

  • Medical Oncology, Hospital del Mar, Barcelona, Spain

  • Servico de Haematologia, Hospital das Clinicas da FMUSP, Sao Paulo, Brazil

  • Unite de Recherche en Hematologie et Oncologie, CHAUQ Hopital Enfant-Jesus, Quebec, QC, Canada

Locations

  • Brazil

  • Czech Republic

  • Canada

  • Spain

  • United Kingdom

  • Israel

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

  • B cell lymphomas

  • Neutropenia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • pharmacodynamics

  • fixed dose

  • randomized

  • non inferiority

  • pharmacokinetics

Phase

  • NA

Study Id's

  • NCT00930514

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved